8-KExhibits & Filings

BIOGEN INC. 8-K Report, Exhibit Filing (Oct 22, 2019)

Filed October 22, 2019For Securities:BIIB

Summary

Biogen Inc. announced its third-quarter 2019 financial results on October 22, 2019, via a press release. This filing is primarily an announcement of these results, without detailing specific figures within the 8-K itself, but refers investors to the furnished press release (Exhibit 99.1) for comprehensive information. Investors should consult the press release for details on revenue, earnings, operational performance, and financial condition for the quarter ended September 30, 2019. The information furnished in this 8-K is not considered 'filed' for regulatory purposes such as Section 18 of the Exchange Act, meaning it doesn't carry the same legal implications as a formally filed document. However, it serves as the official notification of the company's performance during the third quarter and is a crucial point of reference for evaluating the company's ongoing business trajectory and market position.

Key Highlights

  • 1Biogen Inc. reported its third-quarter 2019 financial results on October 22, 2019.
  • 2The results were announced via a press release, furnished as Exhibit 99.1 to the 8-K filing.
  • 3The 8-K filing itself does not contain detailed financial figures, directing investors to the press release for specific operational and financial condition information.
  • 4The furnished information is not deemed 'filed' under Section 18 of the Securities Exchange Act of 1934.
  • 5Investors are directed to Exhibit 99.1 for detailed quarterly performance data.
  • 6This filing serves as an official announcement of the company's Q3 2019 performance.

Frequently Asked Questions

The specific financial results for Biogen's third quarter ended September 30, 2019, are detailed in the press release furnished as Exhibit 99.1 to this 8-K filing.

No, this 8-K filing primarily announces that Biogen issued a press release regarding its third-quarter results. The detailed financial statements and performance metrics are contained within the press release itself (Exhibit 99.1).

The statement indicates that the information in the press release, while provided to the SEC, is not subject to the same legal liabilities under Section 18 of the Securities Exchange Act of 1934 as information that is formally 'filed'. However, it remains an official communication of the company's results.

Biogen officially announced its third-quarter 2019 results on October 22, 2019, the same date this 8-K filing was made.